Abraham Bout
Vorstandsvorsitzender bei Bioceros Holding BV
Profil
Abraham Bout is currently the Chairman & Chief Executive Officer at Bioceros Holding BV.
He is also a Member of the Supervisory Board at Polpharma Biologics Utrecht BV.
Previously, he served as the Director at Adenovirus Research Group and as the Principal at Crucell NV.
He was also a Member at Cellutions, Inc. and the Vice President-Protein Production at Janssen Vaccines & Prevention BV.
Additionally, he held the position of Chief Technology Officer at ProFibrix BV.
Dr. Bout obtained his undergraduate and doctorate degrees from the University of Amsterdam.
Aktive Positionen von Abraham Bout
Unternehmen | Position | Beginn |
---|---|---|
Polpharma Biologics Utrecht BV
Polpharma Biologics Utrecht BV Miscellaneous Commercial ServicesCommercial Services Polpharma Biologics Utrecht BV operates as a biopharmaceutical research and development company. It specializes in the development of monoclonal antibodies generation, cell line, upstream process, downstream process, analytical, and bioassay development services. The company is headquartered in Utrecht, the Netherlands. | Direktor/Vorstandsmitglied | - |
Bioceros Holding BV
Bioceros Holding BV Miscellaneous Commercial ServicesCommercial Services Bioceros Holding BV develops monoclonal antibodies and generating GMP-ready cell lines. engages in building therapeutic monoclonal antibodies, including targets in oncology and auto-immune diseases. It generates various cell lines that produce proteins ranging from blood proteins and monoclonal antibodies to fusion proteins. The company is headquartered in Utrecht, the Netherlands. | Vorstandsvorsitzender | - |
Ehemalige bekannte Positionen von Abraham Bout
Unternehmen | Position | Ende |
---|---|---|
Janssen Vaccines & Prevention BV
Janssen Vaccines & Prevention BV Pharmaceuticals: MajorHealth Technology Janssen Vaccines & Prevention BV manufactures and supplies biopharmaceutical products. The company was founded in 2000 and is headquartered in Leiden, the Netherlands. | Corporate Officer/Principal | - |
Crucell NV
Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands. | Corporate Officer/Principal | 01.01.2007 |
Cellutions, Inc.
Cellutions, Inc. Medical SpecialtiesHealth Technology Cellutions, Inc. develops proprietary medical devices. It provides proprietary technology and novel device-based treatment for the cosmetic appearance of cellulite. The company was founded in 2004 and is headquartered in Duluth, GA | Corporate Officer/Principal | - |
ProFibrix BV
ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands. | Technik-/Wissenschafts-/F&E-Leiter | - |
Adenovirus Research Group | Direktor/Vorstandsmitglied | - |
Ausbildung von Abraham Bout
University of Amsterdam | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 7 |
---|---|
Polpharma Biologics Utrecht BV
Polpharma Biologics Utrecht BV Miscellaneous Commercial ServicesCommercial Services Polpharma Biologics Utrecht BV operates as a biopharmaceutical research and development company. It specializes in the development of monoclonal antibodies generation, cell line, upstream process, downstream process, analytical, and bioassay development services. The company is headquartered in Utrecht, the Netherlands. | Commercial Services |
Janssen Vaccines & Prevention BV
Janssen Vaccines & Prevention BV Pharmaceuticals: MajorHealth Technology Janssen Vaccines & Prevention BV manufactures and supplies biopharmaceutical products. The company was founded in 2000 and is headquartered in Leiden, the Netherlands. | Health Technology |
Crucell NV
Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands. | Health Technology |
Adenovirus Research Group | |
ProFibrix BV
ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands. | Health Technology |
Cellutions, Inc.
Cellutions, Inc. Medical SpecialtiesHealth Technology Cellutions, Inc. develops proprietary medical devices. It provides proprietary technology and novel device-based treatment for the cosmetic appearance of cellulite. The company was founded in 2004 and is headquartered in Duluth, GA | Health Technology |
Bioceros Holding BV
Bioceros Holding BV Miscellaneous Commercial ServicesCommercial Services Bioceros Holding BV develops monoclonal antibodies and generating GMP-ready cell lines. engages in building therapeutic monoclonal antibodies, including targets in oncology and auto-immune diseases. It generates various cell lines that produce proteins ranging from blood proteins and monoclonal antibodies to fusion proteins. The company is headquartered in Utrecht, the Netherlands. | Commercial Services |